Vaxcyte (NASDAQ:PCVX) Stock: Insider Harpreet Dhaliwal Sells 17,000 Shares

Vaxcyte, Inc. (NASDAQ:PCVX) insider Harpreet Dhaliwal sold 17,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 11th. The shares were sold at an average price of $67.83, for a total transaction of $1,153,110.00. Following the completion of the transaction, the insider owned 68,085 shares of the company’s stock, valued at approximately $4,618,205.55. This trade represents a 19.98% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Vaxcyte Trading Down 2.0%

NASDAQ:PCVX traded down $1.32 during mid-day trading on Friday, hitting $63.37. 623,298 shares of the company’s stock were exchanged, compared to its average volume of 2,025,302. Vaxcyte, Inc. has a fifty-two week low of $42.40 and a fifty-two week high of $90.75. The company has a current ratio of 4.56, a quick ratio of 4.56 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $10.03 billion, a P/E ratio of -7.86 and a beta of 1.31. The company has a 50 day simple moving average of $62.24 and a 200-day simple moving average of $57.65.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings results on Wednesday, November 4th. The company reported ($1.99) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.11) by $0.12. During the same quarter last year, the firm earned ($1.56) earnings per share. As a group, research analysts expect that Vaxcyte, Inc. will post -7.51 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts recently weighed in on PCVX shares. Guggenheim boosted their price objective on shares of Vaxcyte from $116.00 to $125.00 and gave the stock a “buy” rating in a research note on Monday, October 5th. Needham & Company LLC raised their target price on Vaxcyte from $110.00 to $122.00 and gave the stock a “buy” rating in a research report on Monday, October 5th. Bank of America lowered their target price on Vaxcyte from $133.00 to $130.00 and set a “buy” rating for the company in a research report on Monday, September 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vaxcyte in a report on Friday, October 2nd. Finally, Wall Street Zen raised Vaxcyte from a “strong sell” rating to a “sell” rating in a report on Saturday, August 8th. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Vaxcyte has an average rating of “Moderate Buy” and an average target price of $110.50.

Institutional Investors Weigh In On Vaxcyte

Several institutional investors and hedge funds have recently made changes to their positions in PCVX. Hsbc Holdings PLC lifted its position in shares of Vaxcyte by 4.0% during the 2nd quarter. Hsbc Holdings PLC now owns 4,151 shares of the company’s stock worth $241,000 after buying an additional 159 shares in the last quarter. Nisa Investment Advisors LLC boosted its stake in shares of Vaxcyte by 5.3% in the 3rd quarter. Nisa Investment Advisors LLC now owns 4,189 shares of the company’s stock worth $238,000 after buying an additional 209 shares during the last quarter. Covestor Ltd grew its holdings in shares of Vaxcyte by 31.1% in the third quarter. Covestor Ltd now owns 939 shares of the company’s stock valued at $53,000 after acquiring an additional 223 shares in the last quarter. Meeder Advisory Services Inc. grew its holdings in shares of Vaxcyte by 2.9% in the first quarter. Meeder Advisory Services Inc. now owns 8,335 shares of the company’s stock valued at $484,000 after acquiring an additional 231 shares in the last quarter. Finally, IFP Advisors Inc grew its holdings in shares of Vaxcyte by 72.8% in the second quarter. IFP Advisors Inc now owns 560 shares of the company’s stock valued at $33,000 after acquiring an additional 236 shares in the last quarter. Institutional investors own 96.78% of the company’s stock.

About Vaxcyte

Vaxcyte, Inc. is a clinical-stage biotechnology company developing vaccines to prevent bacterial infectious diseases. Its research focuses on conjugate vaccines, which link bacterial sugars to carrier proteins to help generate an immune response. The company’s pipeline includes VAX-24 and VAX-31, investigational pneumococcal vaccines designed to protect against a broad range of strains, as well as VAX-A1, a candidate targeting Group A Streptococcus. Vaxcyte has no approved commercial vaccines; its programs remain under development.